Enveric Biosciences raises ~$1.5M in registered direct offering with warrants

Enveric Biosciences, Inc.

Sold 328,802 shares at $4.41 per share in a registered direct offering, gross proceeds ~$1.5M.
Concurrent private placement: Series G and H warrants to buy up to 328,802 shares each at $4.16.
Series G warrants expire 5 years after resale registration effective date; Series H expire 18 months after.
Net proceeds ~$1.25M for product development, working capital, general corporate purposes.
H.C. Wainwright acted as placement agent; fees include 7% cash and placement agent warrants.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Enveric Biosciences, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.5 million (effective 2026-01-27).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $1.5 million
Effective: 2026-01-27

Exact text from the filing

On January 27, 2026, Enveric Biosciences, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (each, an “Investor”)

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-004055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.